

Cardio3 BioSciences at EuroPCR Barcelona



**BIOLOGICS
DELIVERY SYSTEMS™**

Cordis Corporation
a **Johnson & Johnson** company





You are Cordially Invited to

Second Generation Cell Therapy for Ischemic Cardiomyopathy The C-Cure programme

FOCUS SESSION (120 mns)

CARDIO3 BIOSCIENCES SCIENTIFIC PROGRAMME



Date: Thursday May 21st 2009

Time: 16:30 - 18:30

Place: EuroPCR - Barcelona

The Forum CCIB Convention Center

Rambla Prim, 1-17

08109 Barcelona, Spain

Room 5

EURO PCR09

Chair: **W. Wijns**

Panelists: **J. Bartunek, A. Behfar, V. Gaussin,
J. Kastrup, M. Bergmann, K. Wollert**

Session Objectives

- * to provide an update on the current status of clinical translation of cell therapy
- * to summarize results obtained with various cell types for heart failure indication
- * to present the science behind the development of novel, 2nd generation cell products
- * to describe the potential of NOGA guidance for cell delivery and tissue targeting
- * to demonstrate a clinical case of application of C-Cure for treatment of ischemic cardiomyopathy in the framework of a clinical randomized trial

Program

Title

- * Introduction & Objectives
- * The clinical problem & unmet needs
- * A patient perspective
- * Stem Cell Therapy so far: status update
- * Why C-Cure: goals & targets
- * Bone Marrow harvest & cell handling
- * Cardiopoiesis of mesenchymal stem cells
 - *Theory & Scientific background*
 - *Practise of cell production*
- * Preclinical efficacy data
- * C-Cure Trial design
- * Early clinical translation:
 - *Which trials? Which end-points?*
- * Percutaneous intramyocardial cell delivery using NOGA
- * C-Cure: Clinical case demonstration
- * Take-home messages

Speaker

- W. Wijns
- M. Bergmann
- J. Bartunek
- K. Wollert
- J. Bartunek
- J. Bartunek
- A. Behfar
- V. Gaussin
- A. Behfar
- J. Bartunek
- Panel Discussion
- J. Kastrup
- J. Bartunek
- W. Wijns